Recombinant meningococcal B vaccine(Chongqing Zhifei Biological Products)(Recombinant meningococcal B vaccine(Chongqing Zhifei Biological Products))

概要

基本信息

药物类型

预防性疫苗

别名

recombinant meningococcal B vaccine(Chongqing Zhifei Biological Products)、recombinant vaccine(Chongqing Zhifei Biological Products)

靶点-

作用方式-

作用机制-

治疗领域

感染

在研适应症

脑膜炎球菌感染

非在研适应症-

原研机构

重庆智飞生物制品股份有限公司

在研机构

重庆智飞生物制品股份有限公司

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)临床前

特殊审评-

关联

3

项与 Recombinant meningococcal B vaccine(Chongqing Zhifei Biological Products) 相关的临床试验

ChiCTR2400084773

/ Suspended临床1期IIT

A Clinical Study on the Intranasally-administered Recombinant Adenovirus Vaccine for the Treatment of Advanced HPV-Positive Oropharyngeal Squamous Cell Carcinoma

开始日期2024-05-31

申办/合作机构-

IRCT20210303050558N1

/ Completed临床3期IIT

Efficacy, safety, and immunogenicity of Soberana recombinant vaccine (product of Finlay Institute) based on RBD protein subunit of Sars-Cov-2 in a 2-dose regimen with and without a booster dose: a double-blind, randomized, placebo-controlled phase III clinical trial in the Iranian population of 18-80 years

开始日期2021-04-25

申办/合作机构-

EUCTR2008-007182-23-GB

/ Not yet recruitingN/AIIT

A phase 2, open-label study of the safety, tolerability and immunogenicity of a Novartis meningococcal B vaccine when administered at a 0, 2, 6 month schedule and of a single dose of Novartis meningococcal ACWY conjugate vaccine in healthy adults aged 18-65 years. - Phase II MenB and MenACWY adult study

开始日期2010-03-16

申办/合作机构

Environmental Protection Agency

100 项与 Recombinant meningococcal B vaccine(Chongqing Zhifei Biological Products) 相关的临床结果

登录后查看更多信息

100 项与 Recombinant meningococcal B vaccine(Chongqing Zhifei Biological Products) 相关的转化医学

登录后查看更多信息

100 项与 Recombinant meningococcal B vaccine(Chongqing Zhifei Biological Products) 相关的专利（医药）

登录后查看更多信息

147

项与 Recombinant meningococcal B vaccine(Chongqing Zhifei Biological Products) 相关的文献（医药）

2025-01-01·Methods in Molecular Biology

Recombinant Vaccine Production: Production of a Recombinant CCHF MVA Vaccine

Article

作者: Hewson, Roger ; Kennedy, Emma ; Dowall, Stuart

One of the key interventions against infection is immunization, including an increasing focus on development of vaccines against pathogenic bunyaviruses. Whilst different vaccine development approaches exist, recombinant viral vaccines have a strong safety record, are rapid to produce, are cost-effective, and have been demonstrated to be rolled out in response to outbreaks, including in low- and middle-income countries. One viral vector, modified Vaccinia Ankara (MVA), has been used to develop vaccine candidates against Crimean-Congo Haemorrhagic Fever (CCHF) virus through incorporation of the nucleoprotein (NP) and glycoprotein (GP) regions, with the former candidate having now progressed to being the first vaccine against CCHF virus to enter Phase 1 clinical trials. Herein, we report the method used to generate this MVA-based vaccine construct.

2024-12-01·Revue medicale de Liege

[Herpes zoster : vaccination and management of satellite lesions in immunocompromised patients].

Article

作者: Nikkels, Arjen ; Delahaye, Thibaut

Shingles, also termed herpes zoster (HZ), is due to the reactivation of the varicella zoster virus (VZV) in a dorsal root nerve ganglion with an intra-axonal passage of the virus to a predetermined dermatome. The risk of HZ increases with age, as well as the morbidity risks. The most feared complication is post-herpetic neuralgia, defined as persisting pain sensations three months after the resolution of the skin lesions. Those risks are even more important in the immunocompromised patient. Currently a recombinant vaccine against HZ reactivation is available with an excellent safety profile. It has demonstrated a very high vaccine protection achieving 97 % for preventing HZ and its complications. A patient presented severe facial HZ with a large number of HZ satellite lesions disseminated over the entire tegumentum. These satellite lesions are a reliable clinical marker for HZ with a high risk for complications. This case underlines the risk of morbidity in the elderly immunocompromised patient as well the fact that HZ is a vaccine preventable disease, currently reimbursed, but not well-known.

2024-10-01·Nature Medicine

The recombinant shingles vaccine is associated with lower risk of dementia

Article

作者: Harrison, Paul J ; Todd, John A ; Taquet, Maxime ; Dercon, Quentin

AbstractThere is emerging evidence that the live herpes zoster (shingles) vaccine might protect against dementia. However, the existing data are limited and refer only to the live vaccine, which is now discontinued in the United States and many other countries in favor of a recombinant vaccine. Whether the recombinant shingles vaccine protects against dementia remains unknown. Here we used a natural experiment opportunity created by the rapid transition from the use of live to the use of recombinant vaccines to compare the risk of dementia between vaccine types. We show that the recombinant vaccine is associated with a significantly lower risk of dementia in the 6 years post-vaccination. Specifically, receiving the recombinant vaccine is associated with a 17% increase in diagnosis-free time, translating into 164 additional days lived without a diagnosis of dementia in those subsequently affected. The recombinant shingles vaccine was also associated with lower risks of dementia than were two other vaccines commonly used in older people: influenza and tetanus–diphtheria–pertussis vaccines. The effect was robust across multiple secondary analyses, and was present in both men and women but was greater in women. These findings should stimulate studies investigating the mechanisms underpinning the protection and could facilitate the design of a large-scale randomized control trial to confirm the possible additional benefit of the recombinant shingles vaccine.

100 项与 Recombinant meningococcal B vaccine(Chongqing Zhifei Biological Products) 相关的药物交易

登录后查看更多信息